Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2023-08-02
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be asked to complete psychological testing and questionnaires as well as an initial MRI and two separate TMS-fMRI sessions. Total participation time across all visits is estimated to be five to six hours.
Research participation will take place at VA Palo Alto as well as at Stanford University.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
rTMS in the Treatment of PTSD
NCT01806168
Effect of TMS on PTSD Biomarkers
NCT04563078
Interleaved TMS-fMRI for Hippocampal Stimulation: Modeling Dose-Response Relationship in Amnestic Mild Cognitive Impairment
NCT05515952
rTMS for PTSD Comorbid With Major Depressive Disorder
NCT02273063
Transcranial Magnetic Stimulation to Improve Functioning in Veterans With PTSD
NCT04207346
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Focal repetitive pulse transcranial magnetic stimulation (rTMS) enables neuromodulation of selected brain regions and connected networks to treat specific symptoms, but the brain targets to support this therapy in PTSD are under discovery. A recent analysis uncovered a brain circuit associated with improvement in anxiety and somatic symptoms following the rTMS treatment of depression. The left hemisphere region with the strongest fMRI functional connectivity with this circuit lies within anatomical area 8Av and the DMN. This association suggests that modulating the DMN through stimulation at left 8Av could be a novel rTMS approach for the treatment of anxiety and may help ameliorate anxiety symptoms in PTSD. This target would be novel since the vast majority of clinical trials of rTMS in PTSD have targeted the right frontal regions of the salience and frontoparietal networks instead of the DMN. One potential reason is that the most established nodes of the DMN do not lie directly below the scalp/skull and are thus unreachable by rTMS.
In this proposal, the overall hypothesis is that left area 8Av can serve as a robust, direct brain target for the DMN, thus facilitating therapy for PTSD and the many other disorders involving the DMN. Researchers will use TMS-fMRI in 30 participants with PTSD to test the causal connections between left 8Av and other regions that could mediate a response. Researchers will test the connectivity between 8Av and the inferior parietal lobe (IPL), a region in the DMN involved in context processing, and other nodes of the DMN (e.g., posterior cingulate, ventromedial prefrontal cortex). Pilot data suggests that the functional connection between 8Av and the IPL to be abnormal in people with anxiety relative to controls and that delivering rTMS to these regions ameliorates anxiety. This proposal will also explore whether stimulation at 8Av modulates the anterior insula, a node of the salience network whose functional connectivity predicts benefit from prolonged exposure therapy in PTSD. The TMS-induced BOLD response in these areas to stimulation of 8Av will be measured and compared to conventional seed-based resting-state fMRI functional connectivity analyses that could serve as an alternative marker for capacity for modulation. In addition, researchers will deliver theta burst rTMS (cTBS) stimulation and study how connectivity changes with respect to baseline. The overall goal is to characterize left 8Av functional connectivity in PTSD, and explore the effects of rTMS stimulation parameters. This project will thus provide a mechanistic understanding of rTMS therapy at 8Av, and will reveal the effects of a novel connectivity-based atlas target.
The participants in the study will come for three visits. During the first visit, participants will undergo MRI, psychological, and functional testing that will be used to characterize them as well as confirm their diagnoses and eligibility for the study. Participants will then undergo simultaneous TMS-fMRI and cTBS and fMRI in the second and third visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TMS-fMRI
Participants will undergo simultaneous TMS-fMRI as part of this study. There will be two locations stimulated: one control region and one target region. Participants will be randomized with respect to the order of receiving stimulation at the locations, but all participants will receive stimulation at both locations as part of the study. All participants will be considered as one group but order effects will be evaluated as an explanatory variable.
TMS-fMRI
Participants will undergo simultaneous TMS and fMRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TMS-fMRI
Participants will undergo simultaneous TMS and fMRI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to maintain a Motor Threshold (MT) with single pulse TMS
* Ability to safely and comfortably undergo an MRI and TMS
* Able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments.
* PTSD diagnosis according to the DSM 5, as determined by the Clinician administered PTSD scale (CAPS-5) criteria.
* Commitment to maintaining a stable medication regimen between the two fMRI sessions
Exclusion Criteria
* Inability to safely and comfortably undergo TMS. TMS exclusions include any history or condition that puts patients at risk.
* Significant dementia as determined by the Montreal Cognitive Assessments (MoCA)
* Common comorbid disorders of Veterans are allowed, but PTSD must be a primary diagnosis causing significant impairment that could not be accounted for by another diagnosis. Medical or mental health conditions that interact with or confound interpretation of PTSD symptoms and anxiety would be exclusionary.
* Being in urgent need of care that would make participation impossible
* Currently taking medications that increase the risk of seizure or influence hemodynamic response
* Presence of any other condition that has the potential to prevent study completion and/or have a confounding effect on the interpretation of results.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Allyson Rosen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Allyson Rosen
Neuropsychologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Allyson C Rosen, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
PAVIR/Palo Alto VAHCS/Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Palo Alto
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Allyson C Rosen, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MH129799
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
ROANEW_0004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.